To Be Discontinued Injection Neurology
Benztropine Mesylate Injecti · 227 days since initial FDA posting
Brand: BENZTROPINE MESYLATE
FDA lists Benztropine Mesylate Injecti as To Be Discontinued (Fresenius Kabi USA, LLC).
No availability text on this FDA row.
Benztropine Mesylate Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Benztropine Mesylate Injection
- Manufacturer
- Fresenius Kabi USA, LLC
- Dosage Form
- Injection
- Presentation
- Benztropine Mesylate, Injection, 1 mg/1 mL (NDC 63323-970-02)
- Package NDC
- 63323-970-02
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Jan 27, 2026
- Last Updated
- Jan 27, 2026
- Therapeutic Category
- Neurology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.